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Tranexamic acid for acute gastrointestinal bleeding (The HALT-IT trial): Statistical analysis 
plan for an international, randomised, double blind, placebo-controlled trial  
 
Abstract 
Background: Acute gastrointestinal (GI) bleeding is an important cause of mortality worldwide. 
Bleeding can occur from the upper or lower GI tract, with upper GI bleeding accounting for most cases. 
The main causes include peptic ulcer / erosive mucosal disease, oesophageal varices and malignancy. 
The case fatality rate is around 10% for upper GI bleeding and 3% for lower GI bleeding. Rebleeding 
affects 5-40% of patients and is associated with a four-fold increased risk of death. Tranexamic acid 
(TXA) decreases bleeding and the need for blood transfusion in surgery and reduces death due to 
bleeding in patients with trauma and postpartum haemorrhage. It reduces bleeding by inhibiting the 
breakdown of fibrin clots by plasmin.  Due to the methodological weaknesses and small size of the 
existing trials, the effectiveness and safety of TXA in GI bleeding is uncertain.  The HALT-IT trial aims 
to provide reliable evidence about the effects of TXA in acute upper and lower GI bleeding.  
Methods: The HALT-IT trial is an international, randomised, double blind, placebo-controlled trial of 
tranexamic acid in 12,000 adults (increased from 8,000) with acute upper or lower GI bleeding. Eligible 
patients are randomly allocated to receive tranexamic acid (1g loading dose followed by 3g 
maintenance dose over 24 hours) or matching placebo. The main analysis will compare those 
randomised to tranexamic acid with those randomised to placebo on an intention-to-treat basis, 
presenting the results as effect estimates (relative and absolute risks) and confidence intervals. The 
primary outcome is death due to bleeding and secondary outcomes are rebleeding, all-cause and 
cause-specific mortality, thromboembolic events, complications, radiological and surgical 
interventions, blood transfusion requirements and disability, defined by a measure of patient’s self-
care capacity. Subgroup analyses for the primary outcome will consider time to treatment, location of 
bleeding, cause of bleed and bleed severity. 
Discussion: We present the statistical analysis of the HALT-IT trial. This plan was prepared and 
submitted for publication before the treatment allocation was un-blinded.  
Trial registration: Current Controlled Trials ISRCTN11225767 (3/07/2012); Clinicaltrials.gov 
NCT01658124 (26/07/2012). 
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Background 
Acute gastrointestinal (GI) bleeding is a common medical emergency and an important cause of 
mortality worldwide. Bleeding can occur from the upper or lower GI tract, with upper GI bleeding 
accounting for most cases. The incidence varies widely depending on the population prevalence of 
risk factors, with a reported incidence of upper GI bleeding of 50-140 per 100,000 across the US, 
Europe and Scandinavia [1–9]. The case fatality rate is around 10% for upper GI bleeding [1,10] and 
3% for lower GI bleeding [11]. Despite evidence suggesting improvements in survival in recent 
decades, the case fatality rate for upper GI bleeding varies from 3-15%, with the highest risk of death  
in patients with upper GI malignancies and varices  [1,3,4,8,10,12–16]. In addition to cause of bleeding, 
other factors associated with mortality include older age, signs of shock, severe bleeding, active 
bleeding, rebleeding and extent of comorbid disease [16–20].  
The main causes of GI bleeding are peptic ulcer disease, erosive mucosal disease, oesophageal varices 
and malignancy [10]. Peptic ulcer disease and erosions due to Helicobacter pylori infection and NSAID 
use are common causes of GI bleeding worldwide [1,6,10,12,19,21–25]. Bleeding from gastro-
oesophageal varices due to liver cirrhosis is an increasing cause of bleeding in the West, but is also a 
major cause in parts of South America, Asia, Africa and the Middle East where there is high prevalence 
of hepatitis or schistosomiasis [26–33]. Symptoms of GI bleeding include hematemesis and coffee 
grounds vomitus, melaena and the passage of fresh red blood in the stool, and clinical signs of shock 
such as hypotension and tachycardia.  
Some patients with GI bleeding initially stop bleeding and have a brief period of haemodynamic 
stability before starting to bleed again. This phenomenon, known as rebleeding, is common and can 
affect between 5% and 40% of patients with acute GI bleeding. Rebleeding is associated with a four-
fold increased risk of death [10,11,16,18,34]. Some of the variation in rebleeding rates may be 
explained by the use of different definitions, including fresh haematemesis or melaena and recurrent 
hypotension or tachycardia within varying timeframes of the index bleed [19]. The risk of rebleeding 
is highest in the days immediately after the index bleed and declines rapidly with time [35–37].  The 
risk factors for rebleeding are related to the lesion responsible for bleeding, but also influenced by 
age, comorbidity and concomitant medications. [16,18].  
Tranexamic acid reduces clot breakdown by inhibiting the breakdown of fibrin clots by plasmin. It 
decreases bleeding and the need for blood transfusion in surgery and reduces death due to bleeding 
in patients with traumatic and postpartum haemorrhage [38–40]. A systematic review and meta-
analysis of tranexamic acid in patients with upper GI bleeding included eight randomised trials with a 
total of 1,702 patients [41]. Although there was a statistically significant reduction in mortality with 
TXA (RR 0.60, 95% CI 0.42-0.87; p=0.007) and a non-significant reduction in rebleeding (RR 0.72, 95% 
CI 0.50-1.03), because of methodological weaknesses in the included trials and the imprecise effect 
estimates from meta-analyses, the effectiveness and safety of tranexamic acid in GI bleeding remains 
uncertain [41].  Moreover, the included trials were too small to assess the effect of tranexamic acid 
on thromboembolic events. The HALT-IT trial aims to provide reliable evidence about the effects of 
TXA in acute GI bleeding.  
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Study methods   
Trial design 
The HALT-IT trial is an international, randomised, double blind, placebo-controlled trial to quantify the 
effects of TXA on morbidity and mortality in adults with significant upper or lower GI bleeding.  
Blinding and randomisation 
Pfizer Manufacturing, marketing authorisation number PL 00057 /0952, manufactures the tranexamic 
acid. Torbay and South Devon NHS Foundation Trust, manufacturing authorisation number MIA (IMP) 
13079, manufactures the placebo (sodium chloride 0.9%). Sharp Clinical Services (UK) Ltd., 
manufacturing authorisation number MIA (IMP) 10284, manufactures the study drug treatment packs 
containing either the active drug tranexamic acid or placebo. The Marketing Authorisation guarantees 
that the product is manufactured and released in accordance with the UK’s Good Manufacturing 
Practice (GMP) regulations. Ampoules and packaging are identical in appearance.    
An independent statistician from Sealed Envelope Ltd (UK) generates randomisation codes to be sent 
to Sharp Clinical Services UK Limited, a GMP certified clinical trial supplies company who prepare trial 
treatment packs in accordance with the randomisation list. Sharp Clinical Services conduct the blinding 
process and first stage Qualified Person (QP) release, which involves complete removal of the original 
manufacturer’s label and replacement with the clinical trial label bearing the randomisation number 
for use as the pack identification. Other pack label text are identical for tranexamic acid and placebo 
treatments and in compliance with requirements for investigational medicinal products. Sharp Clinical 
Services UK are also responsible for maintaining the Product Specification File (PSF) until final database 
lock and unblinding of the trial data. Quality control checks to assure the blinding process are 
performed on a random samples of final QP released drug packs. High Performance Liquid 
Chromatography (HPLC) separation of known TXA is assessed against blinded samples to confirm 
which ampoule contains the placebo and active treatment. The tested samples are unblinded to 
assure accuracy of blinding.  
The Trial Coordinating Centre (TCC) is responsible for assuring all relevant approvals are available at 
the TCC before release of the trial treatment to a site. A separate Manual of Operating Procedures 
details the drug accountability system. The Investigator’s Brochure details labelling of the trial 
treatment and other processes for assuring adherence to Good Manufacturing Practice. 
Eligible patients are randomised to receive either tranexamic acid or placebo as soon as possible and 
the study treatment started immediately. The next consecutively numbered treatment pack is taken 
from a box of eight packs. A fixed loading dosage of 1 g tranexamic acid or placebo (sodium chloride 
0.9%) will be administered, followed by a maintenance dose of 3 g tranexamic acid of placebo (sodium 
chloride 0.9%) infused over 24 hours. 
Ethics approval and consent 
The trial was approved by the UK NRES Committee East of England (reference number 12/EE/0038), 
as well as national and local research ethics committees of participating countries outside of the UK 
(see Additional file X).  
Acute severe GI bleeding can be a frightening condition for the patient and the ensuing blood loss may 
have adverse impact on the patient’s mental and emotional state, impairing their decision-making 
ability.  The consent procedures consider this together with the need to randomise and treat urgently. 
If the patient is fully competent, written consent is sought. If the patient’s capacity is impaired and a 
personal or professional representative is available, consent is sought from the representative. If 
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neither are able to provide informed consent, consent is waived and the patient is informed about the 
trial as soon as it is possible. 
Data collection 
The entry form (Appendix 1) is used to assess eligibility and collect baseline information. Once a 
patient has been randomised, the outcome in hospital is collected even if the trial treatment is 
interrupted or is not actually given. No extra tests are required but a short outcome form (Appendix 
2) is completed from the medical records 28 days after randomisation or on discharge from the 
randomising hospital or on death (whichever occurs first). Any adverse events that become known to 
the investigator are reported up to 28 days after randomisation.  
Sample size 
We originally specified all-cause mortality as the primary outcome because we believed that most 
deaths would be due to bleeding. However, as the trial was underway we observed that over half of 
all deaths were due to non-bleeding causes such as cancer and sepsis (see Figure 1). Tranexamic acid 
reduces bleeding by inhibiting fibrinolysis. Based on this mechanism of action, we do not expect any 
substantial reduction in non-bleeding deaths. This hypothesis is supported by  evidence from trials of 
tranexamic acid in trauma and postpartum haemorrhage [39,40,42]. As such, the treatment effect on 
all-cause mortality will be diluted by non-bleeding causes of death, reducing statistical power [42].  
Death due to bleeding is the relevant endpoint for the HALT-IT trial because it has the potential to be 
reduced by the trial treatment. Fibrinolysis may play an important role in GI bleeding: gastric vein 
blood samples from patients with peptic ulcers contain high concentrations of plasmin and many 
patients with acute upper GI bleeding have elevated levels of fibrin degradation products (a biomarker 
for fibrinolysis) which is associated with worse outcomes [43–45]. The rationale for changing the 
primary outcome from all-cause mortality to death due to bleeding was published in October 2018 
[42]. The decision was supported by the Trial Steering Committee and was made prior to the end of 
the trial and prior to un-blinding and so was not a data-dependent change.  
Assuming a cumulative incidence of death due to bleeding of 4%, a study with 12,000 patients will 
have 85% power (two sided alpha = 5%) to detect a clinically important 25% relative reduction in death 
due to bleeding from 4% to 3%.  
I observed that Organ failure and Sepsis constitute 31.8% second to Bleeding, 43.4%. In view of the 
relationship between the pathogenesis of bleeding (haemorrhagic shock), sepsis (not from infection), 
and organ failure, are we able to actually get the various centres to have a standard definition of the 
three causes of death, that helped us in classifying them separately without any overlap. For instance, 
sever bleeding with haemorrhagic shock is a potential cause of septic shock which may lead to oragn 
failure. Death may occur at any stage of this progression between the three causes of death as 
indicated in the pie chart.  
While it may be a bit late to consider this, tranexamic acid may indeed have prevented more deaths 
from bleeding as the primary cause if the person filling the Outcome of death was unable to have the 
actual cause of death from the clinical parameters or at post mortem, if it was performed.  
Is there any subanalysis that we need to perform without bordering on data exploration or data 
fishing. This  will only make our outcome more real as it can tilt the outcome of the study either way. 
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Figure 1: Causes of death in 
the HALT-IT trial during 
recruitment (Oct 2018) 
Trial population 
Eligibility 
Patients with significant GI bleeding to whom the uncertainty principle applies are eligible. Specifically, 
a patient can be enrolled if the responsible clinician is substantially uncertain as to whether the trial 
treatment is appropriate for that particular patient. Significant bleeding is diagnosed clinically and 
implies a risk of bleeding to death. Patients with significant bleeding may include those with 
hypotension, tachycardia, signs of shock, or those needing urgent transfusion, endoscopy or surgery. 
Patients with a clear indication or contraindication for tranexamic acid are excluded.  
Recruitment, withdrawal and loss to follow-up 
We will display the flow of study participants using a Consolidated Standards of Reporting Trials 
(CONSORT) diagram (see Appendix Figure 1). For each trial arm, we will present the total number 
randomised, the number with baseline data, the number lost to follow up, the number who withdrew 
consent, and the number of participants with outcome data. 
Baseline patient characteristics 
We collect data on the following baseline characteristics: age, sex, time from onset of GI bleeding 
symptoms to randomisation, suspected location of bleeding, clinical symptoms (e.g. haematemesis, 
melaena), suspected variceal bleeding, systolic blood pressure, heart rate, signs of shock, suspected 
active bleeding, major comorbidities, anticoagulation therapy and type of admission. We will present 
the distribution of baseline characteristics (n and %) in the treatment and placebo groups to check 
that randomisation was successful in producing similar groups (see Appendix Table 1).  
Analysis 
Primary analysis 
The main analysis will compare death due to bleeding in those allocated tranexamic acid with those 
allocated placebo on an intention-to-treat basis. We will present the results as effect estimates 
(relative risks) with a measure of precision (95% confidence intervals) and p-value from Pearson’s chi-
squared test (see Appendix Table 2). The effect of tranexamic acid will also be examined graphically 
using cumulative incidence curves (see Appendix Figure 2) [46]. The effects of TXA on death due to 
bleeding in the HALT-IT trial will be set in the context of other trials of TXA in acute severe 
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haemorrhage (The CRASH-2 and Woman trials). Results will be presented in a forest plot with a pooled 
estimate of the treatment effect (see Appendix Figure 3).  
Primary outcome 
Death due to bleeding within five days of randomisation is the primary outcome.  Patients receive 
tranexamic acid (or placebo) for their initial bleed but not for rebleeding episodes. Tranexamic acid 
has a half-life of 2-3 hours so 99% will be eliminated within about 2 days of randomisation [47,48]. We 
do not expect tranexamic acid to reduce deaths from a rebleeding episode several weeks after the 
drug has been fully eliminated, therefore the primary outcome will consider early deaths due to 
bleeding only. Cause of death is assigned by local investigators who provide a narrative of the events 
leading to death. The cause of death narratives are reviewed by the principal investigator (who is blind 
to treatment allocation) and queried if more information is needed to confirm whether death is due 
to bleeding or another cause. 
Secondary outcomes  
Rebleeding 
Rebleeding occurs in approximately 10-25% of patients with acute GI haemorrhage and is associated 
with an increased risk of death due to bleeding [49]. A clinical diagnosis of rebleeding is made by the 
treating clinician based on the presence of any of the following criteria, as defined in a data collection 
guide. These criteria for rebleeding were recommended by a methodological framework for trials in 
GI bleeding following an international consensus conference [50].  
• Haematemesis or bloody NG aspirate > 6 hours after endoscopy. 
• Melaena after normalisation of stool colour. 
• Haematochezia after normalisation of stool colour or after melaena. 
 Development of tachycardia (HR>110 beats per min) or hypotension (SBP<=90mmHg) after 
≥1 hour of haemodynamic stability (i.e. no tachycardia or hypotension) in the absence of an 
alternative explanation for haemodynamic instability, such as sepsis, cardiogenic shock, or 
medication 
• Haemoglobin drop of >2g/dl after two consecutive stable values(<0.5g/dl decrease) ≥3hours 
apart 
• Tachycardia or hypotension that does not resolve within 8 hours after index endoscopy 
despite appropriate resuscitation (in the absence of an alternative explanation) associated 
with persistent melaena or haematochezia.  
• Persistently dropping haemoglobin of >3g/dl in 24 hours associated with persistent melena or 
haematochezia 
It should be noted that patients may continue to have haemodynamic instability, falling haemoglobin 
levels or persistent melaena or rectal bleeding for hours and even days after bleeding has stopped, 
making these patients difficult to categorise; however, these criteria are more likely to indicate 
rebleeding than equilibration [50]. 
 
Rebleeding within 5 days 
Most rebleeding tends to occur within 5 days of the index bleed [35–37]. We believe tranexamic acid 
will be most effective at reducing the risk of rebleeding soon after the index bleed when blood plasma 
concentrations of the drug are above the level needed to inhibit fibrinolysis [51]. To determine 
whether tranexamic acid reduces rebleeding, we will analyse the effect on early rebleeding within 5 
days of randomisation (see Appendix Table 2).  
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Rebleeding within 28 days 
Rebleeding that occurs more than 5 days after randomisation will be defined as late rebleeding. We 
hypothesise that tranexamic acid will be much less effective for late rebleeding occurring days or 
weeks after the drug has been eliminated.  To investigate this we will assess the effect of tranexamic 
acid on rebleeding within 28 days (see Appendix Table 2). If our hypothesis is correct, the inclusion of 
late rebleeding events will dilute the treatment effect. 
 
Death due to bleeding within 28 days 
As with late rebleeding, we do not expect tranexamic acid to have an effect on late deaths due to 
bleeding that occur several days after randomisation. To assess this we will analyse the effect of 
tranexamic acid on death due to bleeding within 28 days of randomisation (see Appendix Table 2). We 
expect to observe a smaller treatment effect when including late deaths due to bleeding. 
 
Mortality  
We will analyse the effect of tranexamic acid on all-cause and cause-specific mortality at 28 days. 
Specific causes of death to be analysed include death due to bleeding, thrombosis, organ failure, 
pneumonia, sepsis, malignancy and other causes (see Appendix Table 3). We will also examine the 
temporal distribution of causes of death by days since randomisation using a frequency bar chart (see 
Appendix Figure 4). Based on its mechanism of action and data from large randomised trials, we do 
not expect tranexamic acid to reduce deaths from non-bleeding causes like cancer or sepsis or to 
reduce late deaths from bleeding.  
 
Endoscopic, radiological and surgical procedures for GI bleeding 
It remains unclear whether tranexamic acid reduces the need for surgery in GI bleeding [41]. In large 
trials of tranexamic acid for postpartum and traumatic haemorrhage, there was no effect on surgical 
interventions except for laparotomy for bleeding [39,40].  If tranexamic acid reduces GI bleeding, it 
has the potential to reduce the need for some surgical, endoscopic and radiological procedures. While 
we do not expect tranexamic acid to influence diagnostic endoscopic and radiological procedures 
planned around the time of hospital admission and randomisation, there is potential to reduce the 
need for diagnostic procedures planned after resuscitation, and therefore  after randomisation [42]. 
Similarly, therapeutic procedures and surgical interventions planned and undertaken after diagnosis 
also have the potential to be influenced by tranexamic acid. We will assess the effect of tranexamic 
acid on diagnostic and therapeutic endoscopic and radiological procedures and surgical interventions 
(see Appendix Table 5). It is not possible to look at procedures by time as this information was not 
recorded. 
 
Blood transfusion 
Since blood transfusion is mostly determined by blood loss prior to randomisation, we do not expect 
to see a marked reduction in the need for blood transfusion with use of tranexamic acid [42]. Major 
haemorrhage protocols dictate the type and volume of blood components patients receive based on 
presenting clinical signs such as blood pressure and estimated blood loss. Furthermore, survivor bias 
could lead to higher transfusion rates in the tranexamic acid group. In keeping with this, a systematic 
review of tranexamic acid for GI bleeding found no reduction in transfusion [41]. Although tranexamic 
acid has the potential to reduce transfusion for blood lost after randomisation e.g. after rebleeding, 
we did not collect data on date and time of transfusion. Any effect on late transfusions is likely to be 
obscured by early transfusions for blood lost pre-randomisation. We will assess the effect of 
tranexamic acid on the use of whole blood or packed red cells, frozen plasma and platelets comparing 
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the frequency of transfusion and the mean number of (adult-equivalent) units transfused (see 
Appendix Table 5). 
 
Thromboembolic events 
An individual patient data meta-analysis of the WOMAN and CRASH-2 trials found no increased risk of 
vascular occlusive events with tranexamic acid [52]. While this finding is reassuring, we cannot exclude 
the possibility of some increased risk with TXA, particularly as patients with GI bleeding are older than 
those with traumatic or postpartum haemorrhage and many have multiple co-morbidities. Older age 
is associated with a pro-coagulation haemostatic profile including elevated fibrinogen and 
plasminogen activator inhibitor 1 and reduced clotting time [53–55]. A systematic review of 
tranexamic acid for the treatment of upper GI bleeding found no difference in the risk of 
thromboembolic events but lacked power [41]. We will examine the effect of tranexamic acid on fatal 
and non-fatal pulmonary embolism, deep vein thrombosis, stroke and myocardial infarction (see 
Appendix Table 6). 
 
Complications 
We will analyse the effect of tranexamic acid on renal, hepatic and respiratory failure, cardiac events, 
sepsis, pneumonia and seizures (see Appendix Table 6). If tranexamic acid reduces death due to 
bleeding, patients in the tranexamic group will survive for longer on average and may therefore be at 
greater risk of complications such as sepsis, pneumonia and organ failure. On the other hand sepsis 
may be the cause of bleeding in some instansis like a massive bleeding from Salmonella typhi infection 
of he small bowel. Death due to bleeding tends to occur soon after bleeding onset whereas infections 
and organ failure take several days to occur, except in bleeding from typoid ileitis . On the other hand, 
if tranexamic acid reduces bleeding it may reduce liver failure because bleeding can lead to the 
deterioration of liver function. Although there is evidence that high-dose tranexamic acid can cause 
seizures, we do not expect to see an increase in seizures with the low dose given in the trial.  
 
Self-care capacity 
Patients self-care capacity will be measured using the Katz Index of Independence in Activities of Daily 
Living (Katz ADL) [56]. Participants’ performance in six functions (bathing, dressing, toileting, 
transferring, continence and feeding) is assessed at the time of discharge from the randomising 
hospital or in-hospital 28 days after randomisation. A score of 1 is assigned to each function the 
individual can perform independently and they are summed to produce a total score. A score of 6 
suggests full function, 4 suggests moderate impairment, and 2 or less suggests severe functional 
impairment.  We expect that reduced blood loss in patients who receive tranexamic acid will result in 
less functional impairment. To assess this hypothesis we will compare the proportion of patients with 
no impairment (6), mild to moderate impairment (3-5) or severe impairment (0-2) in the tranexamic 
acid and placebo groups (see Appendix Table 6). 
 
Adverse events 
Data on the number of Adverse Events (AEs), Serious Adverse Events (SAEs) and Suspected 
Unexpected Serious Adverse Reactions (SUSARs) reported up to 28 days after randomisation will be 
presented. We will present a summary table in an appendix to describe the type of AE, Medical 
Dictionary for Regulatory Activities (MedDRA) preferred term (PT), MedDRA System Organ Class (SOC) 
and the number of occurrences and outcomes (completely recovered, recovered with sequelae, or 
died) in the tranexamic acid and placebo groups. With events grouped by MedDRA SOC, we will 
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compare the frequency of events between trial arms using a chi-squared test or Fisher’s exact test 
(see Appendix Table 7).  AEs with evidence that they may be increased by tranexamic acid (i.e. seizures 
and thromboembolic events), will be analysed on an individual basis as well as recurrent episodes of 
gastrointestinal bleeding reported as AEs. 
 
Subgroup analyses 
We will conduct the following subgroup analyses for the primary outcome of death due to bleeding 
by fitting interaction terms with randomised group in a regression model. Interaction tests (the Wald 
test) will be used to explore whether the effect of treatment (if any) differs across these subgroups. 
Results will be presented as crude and adjusted effect estimates with a measure of precision (95% 
confidence intervals) and p-value (see Appendix Table 4). Significant heterogeneity between 
subgroups is required and not just significance of a result in a specific subgroup [57]. Selection of 
potential confounders is based upon review of unblinded data within the trial to date. 
Time to treatment (<=3h, >3h) 
Trials of tranexamic acid in traumatic and postpartum haemorrhage provide evidence that early 
treatment (within 3 hours of bleeding onset) confers the most benefit, while late treatment is 
ineffective [39,52,58]. As such, we plan to conduct a subgroup analysis of the treatment effect 
stratified by time to treatment. Patients with GI bleeding may not experience symptoms immediately 
so time of symptom onset accurately reflect time of bleeding onset. Time to treatment may therefore 
be underestimated. Because few patients are treated early (within 3 hours), there may be low power 
to detect an interaction if one exists. As such, we will analyse time to treatment as both a categorical 
(<=3h, >3h) and continuous variable because the latter will preserve more information so should have 
more power. Because there is prior evidence to expect a time to treatment interaction, we do not 
require as strong evidence against the null hypothesis of homogeneity as we might usually require. 
Most trials lack power to detect heterogeneity in treatment effects and the lack of a statistically 
significant interaction does not mean that the overall treatment effect applies to all patients. Because 
there is prior evidence that early treatment is more effective, we will consider the time to treatment 
sub-group analysis in the context of the existing data (in particular data from the CRASH-2 and 
WOMAN trials) on the time to treatment interaction and will rely more on scientific judgment than on 
statistical tests.  
Early treatment is correlated with certain bleed characteristics (upper GI bleed, suspected active 
bleeding and suspected variceal bleeding) and patient characteristics (younger age, low systolic blood 
pressure and heart rate, clinical signs of shock and comorbidities, especially liver disease) (see Figure 
1). Some of these characteristics confer a higher clinical Rockall score suggesting patients with more 
severe bleeding are treated earlier. Since these factors are also associated with mortality, they could 
confound the interaction between time to treatment and the treatment effect. We will control for 
age, systolic blood pressure, heart rate, location of bleeding, suspected active bleeding and comorbid 
liver disease in a Poisson model with robust error variance. Signs of shock and liver disease may be 
collinear with heart rate or blood pressure and suspected variceal bleeding, respectively, so they will 
not be included in the model.  
Location of bleeding (upper GI, lower GI) 
We will examine the effect of tranexamic acid on death due to bleeding stratified by location (upper 
versus lower GI). Evidence suggests the rates of rebleeding and mortality after upper and lower GI 
bleeding are similar [34], and there is no reason to  expect  the  effect  of  tranexamic  acid  to  vary  
substantially by location of bleeding in the GI tract. Location of bleeding and death due to bleeding 
are both associated with age, shock, systolic blood pressure, heart rate, comorbidities (especially liver 
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disease), suspected variceal bleeding and time to treatment. We will adjust for these potential 
confounders in a multivariable model excluding suspected variceal bleeding and shock due to 
potential collinearity. Unless  there  is  strong  evidence  against  the  null  hypothesis  of  homogeneity  
of  effects  (i.e.  p<0.001),  the overall  relative  risk  will  be  considered  the  most  reliable  guide  to 
the approximate treatment effect in all patients. 
Suspected variceal bleeding and comorbid liver disease (yes, no/unknown)  
Outcomes in acute GI bleeding vary by cause of haemorrhage. Variceal bleeding is associated with the 
highest risk of rebleeding and death. Oesophageal varices are dilated submucosal veins that usually 
develop because of portal hypertension, often due to cirrhosis. Haemostasis is disturbed in patients 
with liver disease because many of the pro- and anti-coagulation factors and components of the 
fibrinolytic system are produced by hepatic parenchymal cells in the liver, although the overall sum of 
effects are debated [59–61]. Any resulting imbalance in coagulation or fibrinolysis may alter the 
antifibrinolytic activity of tranexamic acid; however, the direction of this potential effect remains to 
be determined. We will examine the effects of tranexamic acid on death due to bleeding in patients 
with suspected variceal bleeding and comorbid liver disease compared to other or unknown causes of 
bleeding. These patients are more likely to be treated early, be younger and have suspected active 
bleeding, signs of shock and lower systolic blood pressure and heart rate. We will control for these 
potential confounders in a multivariable model, excluding shock and suspected variceal bleeding due 
to potential collinearity. Unless  there  is  strong  evidence  against  the  null  hypothesis  of  
homogeneity  of  effects  (i.e.  p<0.001), the overall relative risk will be considered the most 
appropriate measure of effect.    
Clinical Rockall score (1-2, 3-4, 5-7) 
We will assess the effect of tranexamic acid stratified by the clinical (pre-endoscopy) Rockall score, a 
widely used risk scoring system for GI bleeding. The score is derived from age, comorbidities, signs of 
shock, heart rate and systolic blood pressure, all of which are independent predictors of mortality. 
Although originally developed for upper GI bleeding [18], the Rockall score has also been shown to be 
predictive of mortality in lower GI bleeding [34]. Because patients with a higher Rockall score tend to 
be treated earlier and have suspected variceal bleeding and suspected active bleeding, we will control 
for these variables in a multivariable regression model. We do not expect the treatment effect to vary 
by Rockall score. Unless there is strong evidence of an interaction (p<0.001), we will present to overall 
relative risk as the most appropriate measure of effect.  
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Figure 1: Potential confounding factors in the subgroup analysis of time to treatment 
 
Per protocol analysis 
We will conduct a per protocol analysis of the effect of tranexamic acid on death due to bleeding 
excluding patients who received neither the loading nor maintenance dose or received off-label TXA 
during the trial. We expect to observe a slightly larger treatment effect in the per-protocol analysis. If 
some patients allocated tranexamic acid did not actually receive it then the treatment group will be 
more similar to the placebo group, thereby diluting the treatment effect. Similarly, if some patients in 
the placebo group receive off-label TXA, this will also cause bias towards the null. 
Missing data 
Based on the data collected to date, we expect loss to follow-up to be minimal (i.e. less than 1% 
missing data on the primary outcome). Any missing values will be reported but not imputed. 
Other analyses to be reported in separate publications 
Survival analysis to investigate the timing and duration of the treatment effect 
We will conduct a survival analysis to explore the effect of tranexamic acid on rebleeding and death 
due to bleeding in more detail. In large trials of tranexamic acid for traumatic (CRASH-2) and 
postpartum haemorrhage (WOMAN), there were few late bleeding-related events. The precise timing 
and duration of tranexamic acid’s antifibrinolytic effect remain to be determined. For example, it is 
unclear whether the treatment effect persists after the drug has been eliminated. Bleeding-related 
events occur later in acute GI bleeding, partly due to rebleeding, so the HALT-IT trial presents a unique 
opportunity to investigate this question.  
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We will report the median survival time and the cumulative incidence in the treatment and placebo 
groups, and model the treatment effect. Cox proportional hazards modelling assumes the hazards in 
the treatment and placebo groups are proportional over time. This assumption may be invalid if the 
antifibrinolytic effect of tranexamic acid declines over time as the drug is metabolised. We will 
formally assess this using the Royston-Palmer test for proportional hazards - a combined test with 
increased power when an early treatment effect is present [62]. If the treatment effect on death due 
to bleeding and rebleeding appears to change with time (non-proportional hazards), we will examine 
this in detail using various methods, firstly by including a time by treatment interaction term in the 
model. We will also estimate average cumulative hazard ratios for increasingly longer periods of 
follow-up. This method is preferred to period-specific hazard ratios, which can be susceptible to 
selection bias [63]. Nevertheless, we will also use lexis expansion to calculate period-specific hazard 
ratios and test for interactions between treatment group and period.  If we are able to identify the 
average duration of the treatment effect, we will examine whether this varies by baseline 
characteristics including time to treatment, bleeding severity, cause of bleeding and age. 
Death due to bleeding is a competing risk for non-bleeding causes of death and vice versa. Death is 
also a competing risk for rebleeding. We will estimate the treatment effect using a proportional cause-
specific hazards model in which competing events are censored. The proportional cause-specific 
hazards model is preferred for aetiological research; however, both the cause-specific hazard and 
cumulative incidence can provide insights into a treatment’s effects [64,65]. As such, a subdistribution 
hazards model and Gray’s test for comparing cumulative incidence functions will be presented as a 
supplementary analysis [66,67].  Risk of rebleeding is highest immediately after the index bleed, death 
is a competing risk for rebleeding and some patients may experience more than one episode during 
the follow-up period. A survival analysis of the effect of tranexamic acid on rebleeding will take into 
account timing of events, competing risks and dependence among repeated events. 
Cost effectiveness analysis 
If the trial demonstrates that tranexamic acid is an effective treatment for GI bleeding, we will conduct 
an economic evaluation to determine cost-effectiveness. Broadly speaking the methods will mirror 
those used by Li et al. who assessed the cost-effectiveness of tranexamic acid for the treatment of 
women with post-partum haemorrhage [68].  
The analysis will compare tranexamic acid against clinical practice without tranexamic acid.  A cost-
utility analysis will be performed from a health services cost perspective with outcomes expressed as 
Quality-Adjusted Life-Years (QALYs).  The analyses will be performed separately for a set of different 
countries, depending on where the majority of people have been recruited, but is likely to include at 
least the UK and Pakistan. A decision model will be used to extrapolate results from the trial into the 
longer term.  Resource data, such as drugs and length of inpatient stay, are collected as part of the 
trial and will be analysed accordingly. Both deterministic and probabilistic sensitivity analysis will be 
undertaken. Results will also be presented by subgroups if considered appropriate. 
Impact of baseline risk on treatment effectiveness  
To assess whether the effect of tranexamic acid on death due to bleeding varies by baseline risk we 
will build a prognostic model using baseline characteristics identified as important predictors of death 
due to bleeding. Prognostic factors include age, systolic blood pressure, heart rate, suspected location 
of bleeding, haemetamesis/coffee ground vomitus, suspected variceal bleeding, suspected active 
bleeding, comorbidities and country. The prognostic model will then be used to stratify patients by 
risk of mortality and stratum-specific effect estimates (relative risk) and 95% confidence intervals will 
be calculated. We do not expect the treatment effect to vary by baseline risk. Unless there is strong 
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evidence against the null hypothesis of homogeneity of effects (P<0.001), the overall  relative  risk  will  
be  considered  the  most  reliable  guide  to the approximate treatment effect in all patients. 
Adjustment for baseline risk  
Due to the large size of the HALT-IT trial, baseline characteristics should be well balanced between the 
treatment and placebo groups so that any differences in outcomes is due to the treatment. There is 
still a small possibility, however, that some imbalance in baseline risk may have arisen by chance. If 
prognostic factors are distributed differently across the treatment and placebo groups, this could bias 
the treatment effect. To investigate this hypothesis, we will conduct an analysis of the treatment 
effect on death due to bleeding adjusted for baseline risk. Patients will be stratified by risk deciles 
based on the predicted probability of death due to bleeding and a pooled effect estimate (relative 
risk) will be calculated using inverse variance weighting. This will provide an estimate of the treatment 
effect un-confounded by baseline risk. 
Centre and country effects 
Centre and country-level characteristics can influence patient outcomes. For example, differences in 
outcome may be related to resource availability or clinical practice. We will present a graph showing 
the number of patients and bleeding deaths by country and will use multivariable regression modelling 
to examine the treatment effect by country, including an interaction term between county and 
treatment. We will adjust for potential confounders including age, systolic blood pressure, heart rate, 
comorbidities, location of bleeding, suspected variceal bleeding, suspected active bleeding and time 
to treatment. A comparison between low, middle and high-income countries will be included using 
the World Bank country groupings by income. We do not expect the effect of tranexamic acid on the 
risk of death due to bleeding to vary by country even though the absolute risk will vary due to 
between-country differences in patient populations. Countries recruiting less than 100 patients will 
be omitted from the analysis as necessary. 
It has been proposed that between-centre differences in outcome may influence the estimation of 
the treatment effect. We will use a random effects regression model to examine whether there is 
significant heterogeneity in death due to bleeding by centre. Results will be presented in the form of 
a forest plot. Prognostic patient characteristics (age, systolic blood pressure, heart rate, comorbidities, 
location of bleeding, suspected variceal bleeding, suspected active bleeding), treatment group and 
time to treatment will be adjusted for.  To take into account country-level effects we will also consider 
between-centre differences in outcome adjusted for country. We will then use fixed and random 
effects regression to estimate the treatment effect before and after accounting for between-centre 
differences, assuming a constant treatment effect across centres. To assess whether the treatment 
effect differs by centre, will fit a model with an interaction term between centre and treatment. 
Data monitoring 
The progress of the HALT-IT trial, including recruitment, data quality, outcomes and safety data, are 
reviewed by an independent Data Monitoring Committee, which can decide to reveal unblinded 
results to the Trial Steering Committee. To date, four interim analyses have been conducted. 
Data sharing 
To maximise data utilisation and improve patient care, the trial data will be made available via our 
online data-sharing portal - The Free Bank of Injury and emergency Research Data (freeBIRD) 
(http://freebird.Lshtm.ac.uk) - once primary and secondary analyses have been published. 
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Trial status 
The study has been actively recruiting since July 2013. End of recruitment is planned for 31 May 2019, 
with end of follow-up on 30 June 2019. Further information is available at http://haltit.Lshtm.ac.uk/.  
Discussion 
We present our plan for the statistical analysis of the HALT-IT trial prior to the end of recruitment, 
database lock and un-blinding in order to avoid data-dependent analyses. We set out a priori 
hypotheses and propose ways to test these. We also provide the rationale for changing the primary 
outcome from all-cause mortality to death due to bleeding within 5 days of randomisation. 
List of abbreviations 
AE = adverse event; CRASH-2 = Clinical Randomisation of an Antifibrinolytic in Significant 
Haemorrhage; GI = gastrointestinal; GMP = Good Manufacturing Practice; HALT-IT = Haemorrhage 
alleviation with tranexamic acid – Intestinal system; HPLC = High Performance Liquid Chromatography; 
HR  = heart rate; Katz ADL = Katz Index of Independence in Activities of Daily Living; MedDRA = Medical 
Dictionary for Regulatory Activities ; MedDRA PT = Medical Dictionary for Regulatory Activities 
Preferred Term; MedDRA SOC = Medical Dictionary for Regulatory Activities system organ class; PSF = 
product specification file; QALYs = Quality-Adjusted Life-Years; QP = qualified person; SAE = serious 
adverse event; SBP = systolic blood pressure; SUSAR = suspected unexpected serious adverse reaction; 
TCC = Trial Coordinating Centre; UK = United Kingdom; US = United States; WOMAN = World Maternal 
Antifibrinolytic. 
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